logo
Trump's dysfunctional government can learn from these Republican governors

Trump's dysfunctional government can learn from these Republican governors

Yahoo4 hours ago

President Donald Trump and congressional Republicans are struggling to do their jobs because they are losing focus on what they were elected to do. They are creating political sideshows and distractions from the issues that truly matter to Americans, and the issues that voters wanted Trump to fix.
Instead of fixing the economy, for example, Trump is locked in a social media battle with Elon Musk. Why?
Republicans in control of the federal government should take a note from popular GOP governors who are delivering on what voters actually want without all of the noise that is engulfing the presidency and Congress.
Opinion: Musk is angry Trump used him. I'm frustrated we're focusing on the wrong thing.
Trump has made progress on securing the border, despite his deportation struggles, but the economy is where he struggles. His unpredictable and ill-advised tariff policy has investors worried, and his administration is pushing a bill that would raise the country's deficit.
The old adage 'it's the economy, stupid' rings true even today. If Trump cannot handle the basics of the job, then Americans are unlikely to give him leeway on other issues.
In contrast, Florida Gov. Ron DeSantis is more popular than Trump in the Sunshine State and is overseeing a strong economic run while presiding over a strong public school system. Florida's job growth is outpacing the national average.
Opinion alerts: Get columns from your favorite columnists + expert analysis on top issues, delivered straight to your device through the USA TODAY app. Don't have the app? Download it for free from your app store.
Georgia Gov. Brian Kemp is another example. He enjoys extraordinarily high approval ratings, even though Trump had a narrow victory in the state in 2024. He's done so on the back of good job creation marks and, again, a strong public school system.
These are two Republican governors doing the job we need the federal GOP to do, instead of the bickering we're seeing unfold on social media.
This isn't to say that either of those two governors don't take swings in the culture war. DeSantis is probably best known for his actions against Disney and other social debates. Kemp also has a history of fighting "woke" and dabbling in the culture wars. But in surrounding themselves with competent allies and running the government well, voters give them a longer leash.
The lesson here for Trump is to take care of the basic issues that impact voters, then he can get bogged down in his culture war stances. Both Kemp and DeSantis have gotten away with their antics because they are competent executives.
Opinion: There is no 'reverse discrimination,' people. There is only discrimination.
In state governments, this includes going to the DMV, the quality of public schools and paying taxes. If these types of experiences are painless, people have a more positive view of the government.
Federally, this is reflected in the economy, as people's daily lives are most significantly impacted by the state of the economy. Culture war issues matter at the margins, but people broadly vote based on the economy. Because Trump is struggling with the economy, his actions in other areas are a glaring distraction.
He could stand to ask governors like DeSantis and Kemp about how to lead along conservative principles without all the mess and failure.
Dace Potas is an opinion columnist for USA TODAY and a graduate of DePaul University with a degree in political science.
You can read diverse opinions from our USA TODAY columnists and other writers on the Opinion front page, on X, formerly Twitter, @usatodayopinion and in our Opinion newsletter.
This article originally appeared on USA TODAY: Kemp, DeSantis show Trump how Republicans should govern | Opinion

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

Associated Press

time8 minutes ago

  • Associated Press

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas' registration statement for the initial public offering held on or about September 13, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 8, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zenas BioPharma, Inc. ('Zenas' or the 'Company') (NASDAQ: ZBIO) and reminds investors of the June 16, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Zenas BioPharma materially overstated the amount of time it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and (2) as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared. When the true details entered the market, the lawsuit claims that investors suffered damages. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Zenas' conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Zenas BioPharma class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action

Associated Press

time8 minutes ago

  • Associated Press

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action

NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Organon & Co. (NYSE: OGN) between October 31, 2024 and April 30, 2025, both dates inclusive (the 'Class Period'), of the important July 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased Organon securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Organon class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 22, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Organon's priorities, particularly, related to capital allocation through quarterly dividends. Notably, defendants concealed the high priority of Organon's debt reduction strategy following Organon's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Organon class action, go to call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store